PET (positron emission tomography) beats SPECT (single photon emission computed tomography) as heart risk diagnostic
This article was originally published in Clinica
Positron emission tomography (PET) scanning is more accurate, less invasive and more cost effective than single photon emission computed tomography (SPECT) imaging when used as the first tool to diagnose cardiac vessel blockages. So suggest the results of a trial conducted at the State University of New York, published in the July edition of the Journal of Nuclear Medicine. Lead researcher Dr Michael Merhige, clinical associate professor of nuclear medicine at the university, said that the researchers found a more than 50% decrease in the use of invasive coronary arteriography and coronary artery bypass grafting when PET was used as the first-line test.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.